FIELD OF THE INVENTION
The present invention relates to novel compositions, methods and test kits which use the procedure of pho toaf?nity labeling with nucleotide affinity probes, to detect disease using cerebral spinal ?uid, blood, tissue, or other specimens in a mammal. The present invention provides a method of diagnosis based on a disease speci?c biochemical marker macromolecule which, if present, can be identi?ed in a small biological sample from a patient. In particular, the present invention con cerns a method for diagnosing particular disease states using a disease-speci?c nucleotide binding protein and detecting the binding of that protein in the serum or cerebral spinal ?uid of a patient afflicted with that dis ease.
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is an idiopathic progressive dementia that will affect a large percentage of our aging population. To date its etiology is still unknown. The neurodegenerative disease is characterized by a chroni cally deteriorating course of impaired intellectual func tion and memory loss.
Relatively little is known of the pathophysiological chain of events that leads to the premature dysfunction and death of affected neurons in Alzheimer's disease patients. Multiple abnormalities have been reported in the brains of patients who have been diagnosed as hav ing Alzheimer's disease, but it is dif?cult to determine which of these are the result of brain damage and which contribute to premature neuronal dysfunction and death.
At the present time, the clinical diagnosis of Alzhei mer's disease is one of exclusion. Secondary causes of loss of memory and impaired cognitive function may result from multiple infarcts, leading to so-called multi infarct dementia, or from intracranial mass lesions, such as subdural hematomas, brain tumors, or granulomas. Central nervous system infections of viral and bacterial origin, or even slow viral disorders such as Creutzfeldt~ Jakob disease, are part of the differential diagnosis.
Furthermore, metabolic disorders involving vitamin B12 metabolism, thiamine or folate de?ciency, thyroid dysfunction, hepatic and renal failure, as well as drug toxicity may appear as dementia. Nevertheless, when all these secondary causes, many of which are reversible, are eliminated, cerebral atrophy of unknown cause or
Alzheimer's disease still covers the largest number of patients. Nos. 4, 666, 829, 4, 701, 407, 4, 816, 416 and 4, 933, 156. However, amyloid deposits are also found in the brains of aged individuals who have never displayed signs of dementia. For example, a recent article (J. Biol. Chem, 265:15977 (1990) ) has shown that there were no differences in the primary structure of precursor amy loid protein from platelets of normal individuals and that of Alzheimer's disease patients. Therefore, while amyloid protein may be involved in Alzheimer's dis ease, other methods have been pursued to identify char acteristics more uniquely related to a patient with Alz heimer's disease. For instance, U.S. Pat. No. 4, 727, 041,  issued to Aroonsakul, discloses a comparative test for the diagnosis of Alzheimer's disease in humans by deter mining levels of somatotropin and somatomedin-C in the patient's blood sera drawn at intervals following administration of an L-dopa provocative test.
Immunoassay methods have also been developed for detecting the presence of neurochemical markers in Alzheimer's disease patients. U.S. Pat. Nos. 4, 728, 605 and 4, 801, 533, issued 91:613-633 (1983) . In particular, 2-and 8-azido ana logues of purine nucleotides have been used as site di rected photoprobes to identify nucleotide binding pro teins in crude cell extracts. Owens & Haley, J. Biol. Chem. 259:14843-14848 (1984) ; Atherton et al., Bio. of Reproduction, 32:155-171 (1985) . The 2-and 8-azido nucleotides have also been used to map nucleotide bind ing domains of puri?ed proteins. Khatoon et al., Ann. of Neurologz, 26:210-215 (1989) ; King et al., J Biol. Chem, 264:10210-10218 (1989); and Dholakia et al., J. Biol. Chem, 264:20638-20642 (1989) .
Photoaf?nity probes have been used to determine speci?c nucleotide binding sites on a biologically active recombinant peptide molecule. Campbell et al., PNAS, 87:1243 PNAS, 87: -1246 PNAS, 87: (1990 . The probes have also been used to study enzyme kinetics of puri?ed proteins. Kim et al., J. Biol Chem, 265:3636-3641 (1990 Yet a further object of the present invention is to provide a method for aiding in the diagnosis of a spe ci?c neurological disease wherein the neurological dis ease shows an elevation of one or more proteins readily observable after dialysis or ?ltration of the small mole cules away from the proteins of CSF.
A still further object of the present invention is to provide a method for aiding in the diagnosis of other disease states, including non-neural disease states, such as cancer, wherein a sample obtained from a patient suffering from that disease shows an elevation or a de crease in one or more proteins that are detectable by photoaffinity labelling.
Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art on examination of the following description, or may be learned by practice of the inven tion. 
BRIEF DESCRIPTION OF THE DRAWINGS

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION
In accordance with the present invention, novel com positions, methods and test kits are provided, using the procedure of photoaf?nity labeling with nucleotide affinity probes, to detect a neurological disorder using cerebral spinal ?uid, blood, tissue, or other biological samples from a mammal. The presence or development of a neurological or psychiatric disorder can be de tected. The invention concerns a composition, the prep aration of the composition and a method for diagnosing or detecting Alzheimer's disease. The method involves the use of a disease-speci?c nucleotide binding protein within the extracted cerebral spinal ?uid of a patient af?icted with a neurological disorder such as Alzhei mer's disease.
The present invention provides a method for detec tion using a disease-speci?c biochemical marker macro molecule which, if present, can be identi?ed in a small biological sample obtained from a patient. The speci?c biochemical marker macromolecule is dependent on the disease state which is being detected.
The standards for testing for neurological disease states are established by obtaining cerebral spinal ?uid samples from a number of patients, each of whom suf fers from a particular disorder which is clinically mani fested by marked dementia or de?ciency in cognitive function, including memory or attention.
Speci?cally the neurological diseases of the nervous system, referred to in the method of the present inven tion are those diseases, disorders, or syndromes which In addition photoaf?nity compounds of the invention may also include photoactive coenzyme analogs of NAD+, exempli?ed by nicotinamide 2-azidoadenosine dinucleotide (2-azido-NAD+), or analogs of NADH, exempli?ed by nicotinamide Z-hydrazidoadenosine di nucleotide (2-azido-NADH).
Alternatively, guanine moieties can be de?ned in each of the exemplary compounds in place of the re spective adenine moieties. Therefore, certain most pre ferred compounds of the present invention are synthe sized from azidoguanosine 5'-triphosphates or combina tions thereof, or from azidoguanosine 5'-triphosphates and ATP. The latter provides a (2'-5')oligomer contain ing both guanylyl and azidoguanylyl moieties.
Furthermore, photoaf?nity compounds of the present invention may also include, for example, pyrimidine derivatives. For instance, photoactive analogs of dUTP, such as 5-azido-2'-deoxyuridine 5'-triphosphate (5 N3dUTP), may be synthesized from dUMP and provide a pathway for the synthesis of other useful 5-substituted uridine nucleotides. The S-diazouridine nucleotides may, for example, serve as active-site-directed photoaf ?nity probes or as substrates for polymerizing enzymes to generate additional photoactive nucleic acids which remain stable to extremes of pH and which remain ef fective photolabeling reagents in the presence of reduc ing agents. Moreover, since the synthesis of S-NgdUTP employs mild conditions, it is also possible to synthesize homopolymers of 5-N3dUTP to provide single-stranded photoactive DNA of de?ned length. Using 5N3UTP one can similarly produce photoactive RNA.
Generalized methods for the synthesis of aryl azides include nucleophilic displacement of a bromine, chlo rine or nitro group by an azide ion or the addition of sodium azide to an acidic solution containing a diazo tized primary aromatic amine.
To date the most widely used 8-azidopurine is proba bly 8N3cAMP. One of the advantages of 8N3cAMP is that in mammalian systems there are only two types of proteins that are known to bind cAMP with high affm ity, the cAMP phosphodiesterases and the regulatory subunits of the cAMP-dependent protein kinases. The in Enzymol, 91:613-633 (1983) provide a detailed ac count of preferred procedures for labeling a speci?c biochemical marker macromolecule in a sample with a photosensitive purine triphosphate azide analog.
Temperature of the photolysis reaction between the sample and the selected photoaf?nity label can range from 0° C. to room temperature (25° C.) or above. How ever, the exchange rate between bound and unbound cAMP or 8-N3cAMP approaches negligible levels at 0° C., and is greatly increased at room temperature. Con versely, once 8-N3cAMP is bound to the speci?c mac romolecular marker, it may be cold trapped onto the protein by dropping the temperature to nearly 0° C. Therefore, the most preferred procedure includes prein cubation of the components at room temperature, and photolysis in plates set on ice to reduce the temperature to approximately 0° to 4° C. By the present invention, the sample is preferably incubated at room temperature with the radioactive photoaf?nity probe for approxi mately 0.5 to 1.0 minutes. Most preferably the mixture is vortexed for 6 seconds followed by an additional 24 seconds of mixing, immediately followed by placing the sample on ice for photoactivation.
The concentration of photoaf?nity reagent must be compatible with the binding affinity of the protein to be labeled. Excessively high concentrations, however, can lead to undesirable nonspeci?c labeling which increases linearly with concentration. Best results can be obtained by experimentally determining the optimum concentra tion for photoincorporation. Directly related to the Ionic strength, pH, cofactor, and metal ion concen trations can each affect protein structure, and are readily adjusted by those skilled in the art to achieve optimal labeling conditions. For example, photoincor poration of the photoaf?nity probe 8N3ATP into GS is preferably elevated by the addition of micromolar lev els of Mn2+ metal ion. In addition protein concentration can be determinative of the photoresponse. Also, both ammonia and glutamate (co-substrates) enhance photolabelling if Mg2+ or Mn2+ is present. The higher the protein content of the sample, the denser the solu tion becomes to light. Therefore, in a denser solution, less UV light reaches the photoreagent per unit of time, Detection of the labeled protein occurs following an appropriate, predetermined incubation time to effect a reaction, and is calculated on the basis of the sample and the selected photoaf?nity probe.
The intensity of the photolyzing light is such that maximum photoincorporation can be obtained in a mini mum amount of time without appreciable change in temperature or damage to the biological sample. Prefer~ ably the photolysis is achieved at 254 nm with an ultra violet light source.
Ultraviolet (UV) light is essential for the activation of the photoprobe treated samples, but only a low intensity UV light is necessary. The intensity of the UV light can range from 180 to 800 nW/cm2 by conventional sources to 4000 p.W/cm2 and above when a high intensity source is used to achieve rapid photolysis.
Photolysis times range from 15 seconds to 5 minutes and must be experimentally determined for each reac tion system. For lamps having intensities of 180-800 uW/cmZ, the preferred photolysis time ranges from approximately 30 to 120 seconds, most preferably, pho tolysis is effected in approximately 30 to 60 seconds.
The distance of the light source from the sample is a determinative factor in the conditions of photolysis. A preferred method of the present invention uses an ultra violet light source having suf?cient intensity, about 6200 ].LW/Cm2, positioned at a set distance, about 1 cm from the sample, for a time suf?cient to effect photoac tivation, generally approximately 45 seconds.
The labeled macromolecule is typically separated from the solution containing excess unbound sample and/or label by precipitation, although other recog nized methods of protein puri?cation are possible. Rec ognized methods of precipitation include, but are not limited to addition of an effective protein precipitating agent, such as trichloroacetic acid (TCA), perchloric acid (PCA), acetone, ammonium sulfate polyethylene glycol (PEG) or the like to the sample. PCA or ammo nium sulfate are the preferred precipitating agents in the present method, and PCA is the particularly preferred precipitating agent.
The amount of precipitating agent is determined by the concentration of protein in the sample. The pre ferred concentration of the precipitating agent is that concentration which effectively precipitates the spe ci?c protein from solution. The most preferred concen tration of the precipitating agent is that amount which effectively precipitates the previously activated, photolabeled cerebral spinal ?uid sample. To determine the effectiveness of the precipitation and separation procedures, both the pellet and the su pernatant ?uid are analyzed for protein content.
The precipitated protein may be solubilized and any remaining reaction quenched by any effective, known method. Any azide remaining after photolysis may be de stroyed by the addition of dithiothreitol or its equiva lent, and potential phosphotransfer from the triphos phate derivative N3ATP or N3GTP may be inhibited by chelators such as EDTA. The preferred protein solubilizing agent is a detergent, particularly SDS, most preferably in a protein solubilizing mix (PSM), such as described by Potter & Haley in Meth. in Enzymol, 9lz6l3~633 (1983) The nature of the sample and the size of the speci?c nucleotide binding protein determine the concentration of the gel used, which in turn determines the time for separation and the electrical current which must be applied to best achieve protein separation. The protein fractions of the present invention most preferably may be separated by electrophoresis on an SDS-polyacryla mide gel (SDS-PAGE) or by isoelectric focusing (IEF) or on two dimensional systems (IEFXSDS-PAGE).
Typically, the sample is fractionated on a 10% poly acrylamide gel, run over a period of 2% to 3 hours, with Most preferably, each completed SDS~PAGE gel is stained with an effective amount of CBB to stain the selected protein fragments. However, many times pro teins can be detected by photolabelling that cannot be detected by any protein staining procedure. In particu lar, the completed gel is immersed in a 10% CBB (W/v) solution for about 1 hour. Then the gel is destained in a solution to effectively remove excess stain. Particularly preferred is a destaining solution of 5% acetic acid and 10% isopropyl alcohol applied for 10418 hours.
Finally, the speci?c binding protein fragments may be visualized by standard autoradiography techniques.
The use of an intensifying screen effectively accelerates the visualization process of autoradiography. By the method of the present invention, the stained gel is dried, and then exposed to DuPont Cronex 4 X-ray ?lm. The autoradiographic procedure is for variable time periods depending on the speci?c activity of the probe photoin serted into the proteins of each experimental sample.
Alternately, if maintained at -70° C., the gel can be subjected to autoradiographic procedures while still in the gel state.
The amount of protein, as well as the radioactivity incorporated into each protein, can be quanti?ed by known methods including, but not limited to, densito metric scans of the exposed X-ray ?lm, or of the stained gel, or by liquid scintillation spectrometry of the protein band following excision from the gel.
Analyses of cerebral spinal fluid taken from human patients suffering from certain neurological or psychiat The 42,000 M,protein is present in the cerebral spinal ?uid of Alzheimer's disease patients in very small quan tities. However, other than albumin and a protein of about 28,000 M,, the 42,000 M, protein is the major protein known to photolabel with either 8N3ATP or 2N3ATP at the concentrations used. Therefore, by using the technique of photoaf?nity labeling and the materials and methods of the present invention, it is possible to detect a very minor protein of cerebral spi~ nal ?uid that interacts with ATP and GTP, and which appears to be unique in the cerebral spinal ?uid of clini cally diagnosed Alzheimer's disease patients.
Also important for the diagnosis of other disease states is the dramatic appearance of other smaller mo lecular weight proteins that photolabel only after ?ltra tion. One of these small proteins is tumor necrosis factor (T NF) which is proposed to be elevated in several dis ease states, including ischemia and AD. Also present is acidic ?broblast growth factor (aFGF). Studies with several different CSFs from neurological diseases show that these proteins change dramatically in different disease states.
Other biological response modi?ers (i.e., cytokines, growth factors, etc.) reportedly in this lower molecular weight region of CSF ?uids include nerve growth fac~ tor (NGF), interleukin-1 (IL-1), interleukin-2 (IL-2), and basic ?broblast growth factor (bFGF). Fluid levels of each of these factors have been postulated to be in volved in various disease states. Each of these biological response modi?ers, in puri?ed form, are photolabeled with nucleotide photoaf?nity probes (Campbell et al, 
